FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Lexaria Bioscience Corp. (the "Issuer").

Trading Symbol: LXX

Number of Outstanding Listed Securities: 78,637,134

Date: July 3, 2019.

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

(a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.

(b) The term "Issuer" includes the Issuer and any of its subsidiaries.

(c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

   Lexaria Bioscience Corp. ("Lexaria") has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patent in the USA in October, 2016. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including but not limited to cannabinoids, vitamins, NSAIDs, and nicotine.

Lexaria and its subsidiaries are not involved directly or indirectly in the cultivation, processing, distribution, or utilization of cannabis or cannabis derived components. All of Lexaria's consumer products utilize legally sourced hemp and hemp components in their production. Lexaria does have an ancillary involvement risk via out-licensing of its patented technology to licensees that choose to utilize its technology to manufacture products that contain locally or state approved but federally regulated and controlled contents. There can be no guarantee that changes in the regulatory framework and environment will not occur and such changes could have a materially adverse effect on the Company. It is possible some jurisdictions may even interpret Lexaria's ancillary involvement as in contravention with regulations.

On June 21 Lexaria announced the results of its 2019 Annual and Special Meeting. All matters presented to the shareholders were approved by the required vote percentages. A breakdown of the voting is as follows:

Matter Being Voted On	For	Against	Abstain or Withheld	Broker Non-Vote	Percent Approved By
To Elect Chris Bunka as a director	19,320,620	N/A	235,561	23,661,530	98.8%
To Elect John Docherty as a director	19,292,585	N/A	263,596	23,661,530	98.65%
To Elect Nicholas Baxter as a director	19,320,092	N/A	236,089	23,661,530	98.79%
To Elect Ted McKechnie as a director	19,346,679	N/A	209,501	23,661,530	98.93%
To Appoint Davidson & Company LLP as Auditors	41,946,901	N/A	1,270,810	0	97.2%
To Approve Executive Compensation	19,101,153	455,028	0	23,661,530	97.67%
To Approve Executive Compensation Annually	692,428	N/A	181,412	23,661,530	3.54%
To Approve Executive Compensation every two years	345,768	N/A	181,412	23,661,530	1.77%
To Approve Executive Compensation every three years	18,641,658	N/A	181,412	23,661,530	95.32%
To Approve the Equity Incentive Plan	18,936,404	619,777	0	23,661,530	96.83%

See Lexaria's press release issued on June 21, 2019 for further details.

On June 24, 2019 Lexaria, via its subsidiary Lexaria Hemp Corp. as licensor, entered into an intellectual property licensing agreement whereby it has licensed the right to its licensee to produce CBD infused powders for sale to commercial business-to-business third parties located in Canada or the United States, for use in the production of food, beverage, dietary supplement and topical products. The Agreement provides the licensee with certain limited exclusivity provisions and rights of first refusal with respect to CBD-infused powders for use in the production of beverage and food products. The Agreement also provides for the payment of an acceptance fee and the payment of the greater of usage fees or certain minimum performance fees by the licensee.

2. Provide a general overview and discussion of the activities of management.

Please refer to #1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not Applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not Applicable

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

See Item #1 above for details regarding new licensing arrangements with a non-Related Person.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Lexaria terminated its license with Biolog Inc. effective as of June 10, 2019.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not Applicable.

8. Describe the acquisition of new customers or loss of customers.

   Not Applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

   On June 4, 2019 Lexaria announced further results of its animal study which were received through the use of an enhanced version of its DehydraTech™ technology. This enhanced version of the DehydraTech™ technology indicated faster delivery of CBD into the bloodstream and at higher levels (up to 1,098% higher) than in generic industry MCT coconut oil formulations and that levels of CBD observed in the average brain tissue of the animals were 1,937% higher than the levels of CBD observed in the average brain tissue of animals that received an MCT oil formulation.

   For full details please see the Press Release dated June 4, 2019.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

    Not Applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

    Not Applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

    Not Applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

    Not Applicable.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds(1)
Common Shares	200,000	Exercise of Warrants	US$59,000

(1) Proceeds are used for general working capital

15. Provide details of any loans to or by Related Persons.

Not Applicable.

16. Provide details of any changes in directors, officers or committee members.

Not Applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer has sufficient funds for the current fiscal year, but may need to raise additional funds to continue operations thereafter.

On May 31, 2019 the FDA held a public forum to discuss unanswered questions concerning products containing cannabis and cannabis-derived compounds and on June 20, 2019 the FDA extended the submission deadline for filing electronic or written comments from July 2, 2019 to July 16, 2019.

On June 25, 2019 the State of Illinois legalized the purchase and possession of recreational marijuana, including cannabis-infused products containing no more than 500 milligrams of THC. The law is expected to be effective as at January 1, 2020.

The Issuer is not aware of any other trends that manifested themselves in the past month that have an impact on its business or markets, other than general market volatility.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated July 3, 2019.

Christopher Bunka
Name of Director or Senior Officer

"Christopher Bunka"
Signature

Chief Executive Officer
Official Capacity

Issuer Details Name of Issuer **LEXARIA BIOSCIENCE CORP.**	For Month End **June 30, 2019**	Date of Report YY/MM/DD **19/07/03**
Issuer Address **#100, 740 McCurdy Road**		
City/Province/Postal Code **Kelowna, BC V1X 2P7**	Issuer Fax No. **(250) 765-2599**	Issuer Telephone No. **(250) 765-6424**
Contact Name **Alex Blanchard**	Contact Position **Manager Corporate Communications**	Contact Telephone No. **(250) 765-6424 x 202**
Contact Email Address **ir@lexariabioscience.com**	Web Site Address **www.lexariabioscience.com**	